Skip to main content
Gujarat Inject (Kerala) Ltd. logo

Gujarat Inject (Kerala) Ltd. — Investor Relations & Filings

Ticker · 524238 ISIN · INE659F01014 BSE.NS Manufacturing
Open in API
Filings indexed 6 across all filing types
Latest filing 2026-05-25 Earnings Release
Country IN India
Listing BSE.NS 524238

About Gujarat Inject (Kerala) Ltd.

http://www.gujaratinject.in

Gujarat Inject (Kerala) Ltd. specializes in the manufacturing and distribution of intravenous (IV) fluids and large volume parenterals. The company's product portfolio includes essential electrolyte solutions such as Dextrose, Sodium Chloride, and Ringer's Lactate, which are critical for patient hydration and clinical care. Utilizing advanced Blow-Fill-Seal (BFS) technology, the firm ensures high standards of sterility and safety in its production processes. The company serves a broad range of healthcare institutions, including public and private hospitals, clinics, and government health agencies. Its operations focus on providing cost-effective, high-quality medical solutions to meet the demands of the healthcare sector.

Recent filings

Filing Released Lang Actions
Media Release on Audited Financial for Results for Q4 FY26.
Earnings Release Classification · 94% confidence The document is a media release announcing the company’s audited quarterly and full‐year financial results (Q4 FY26 and FY26). It includes key highlights of revenues, profits, order wins, and management commentary but does not present detailed financial statements. This fits the definition of an Earnings Release. Q4 2026
2026-05-25 English
Financial Results for the quarter and year ended on 31/03/2026.
Interim / Quarterly Report Classification · 88% confidence The document is a statutory filing under SEBI LODR Reg 33 reporting the Board’s approval and submission of the audited standalone financial results for the quarter and year ended March 31, 2026. It includes the full Statement of Standalone Financial Results and the Independent Auditor’s Report—i.e., it is the actual financial report rather than a brief highlights announcement or simply an announcement that the report is attached. This falls under a comprehensive interim/quarterly financial report (including audited fourth-quarter results) rather than a full Annual Report (10-K) or mere earnings release. Therefore, it is classified as an Interim/Quarterly Report. FY 2026
2026-05-20 English
Pursuant to Regulations 30, 33 and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors ....
Interim / Quarterly Report Classification · 85% confidence The document is the Board’s outcome letter under SEBI LODR with the audited standalone financial results for the quarter and year ended 31 March 2026, including the independent auditor’s report and full financial statements. It is not a full annual report (10-K) but a regulatory filing of quarterly/periodic financial results containing substantive financial data. This fits the definition of an Interim/Quarterly Report (IR). FY 2026
2026-05-20 English
Appointment of Whole Time Director and Chairman of the company w.e.f. 16/05/2026.
Board/Management Information Classification · 95% confidence The document is an immediate compliance filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 notifying the stock exchange and investors of the resignation of the Managing Director and the appointment/ redesignation of a Whole Time Director. It contains detailed board/management change information under Schedule III disclosures, with no financial statements or earnings data. This fits the Board/Management Information category (Code: MANG).
2026-05-16 English
Resignation of Managing Director and chairman of the company w.e.f. 16/05/2026.
Board/Management Information Classification · 99% confidence The document is an official disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 announcing the resignation of the Managing Director and the appointment of a Whole Time Director. It details changes in the board and key management personnel. This fits the category of Board/Management Information (MANG).
2026-05-16 English
Gujarat Inject Kerala Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2026 ,inter alia, to consider and approve 1. Audited Standalone ....
Regulatory Filings Classification · 91% confidence The document is a formal notice to the stock exchange under SEBI Listing Regulations informing of a Board meeting to consider and approve the audited financial results for the quarter and year ended 31st March 2026. It does not contain the results themselves nor attach any report, nor provide detailed financial data. It is a regulatory announcement of a board meeting rather than the report itself or its publication. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-05-15 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.